Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Castrate Resistant Prostate Cancer × Clear all
NCT01352208 2014-03-24

Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

Astellas Pharma Inc

Phase 1/2 Terminated
13 enrolled
Genitourinary

Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡